An aqueous organ preservation solution includes taurine and L-alanine-L-glutamine and glutamic acid. The organ preservation composition can be stored in a solid state, for example in the form of small particles (e.g. a powder or micronized powder), and be dissolved in water, thereby instantly providing a ready-to-use organ preservation solution.

Disclosed is a method capable of selectively synthesizing cationic lipids by controlling the introduction rate of a fatty acid group with respect to an oligoalkyleneamine by the change of reaction conditions.

Disclosed is a method capable of selectively synthesizing cationic lipids by controlling the introduction rate of a fatty acid group with respect to an oligoalkyleneamine by the change of reaction conditions.

Disclosed herein are water-soluble UV absorbing compounds of Formula I with two quaternary ammonium centers, wherein; ##STR00001##
R is selected from saturated or unsaturated alkyl groups with C.sub.12 to C.sub.22 carbon atoms and R.sub.1 is selected from H or methoxy group. The invention further discloses the synthesis of highly substantive water-soluble UV absorbers containing two quaternary ammonium centers, cinnamidopropyl (2-hydroxypropyl alkyl dimethyl ammonium chloride) dimonium chlorides of Formula I and the compositions containing the same in personal care products.

Disclosed herein are water-soluble UV absorbing compounds of Formula I with two quaternary ammonium centers, wherein; ##STR00001##
R is selected from saturated or unsaturated alkyl groups with C.sub.12 to C.sub.22 carbon atoms and R.sub.1 is selected from H or methoxy group. The invention further discloses the synthesis of highly substantive water-soluble UV absorbers containing two quaternary ammonium centers, cinnamidopropyl (2-hydroxypropyl alkyl dimethyl ammonium chloride) dimonium chlorides of Formula I and the compositions containing the same in personal care products.

The present invention relates to a nucleic acid conjugate represented by the following formula 1: ##STR00001##
wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.

The present invention relates to a nucleic acid conjugate represented by the following formula 1: ##STR00001##
wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.

The present invention provides an additive for electrolytic plating solutions, containing at least one selected from compounds represented by the chemical formulas (1) to (4) given in the present description, an electrolytic plating solution containing the additive for electrolytic plating solutions, and an electrolytic plating method that uses the electrolytic plating solution.

The present invention provides an additive for electrolytic plating solutions, containing at least one selected from compounds represented by the chemical formulas (1) to (4) given in the present description, an electrolytic plating solution containing the additive for electrolytic plating solutions, and an electrolytic plating method that uses the electrolytic plating solution.

A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of the lipidoid in the composition is preferably low, relative to the cationic peptide or polymer.